Skip to content
OpenCapital
Get started

Zevra Therapeutics, Inc. ZVRA Discount and rebate liabilities, less current portion

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×—
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity0×-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept zvra:DiscountAndRebateLiabilitiesNoncurrent.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion?
Zevra Therapeutics, Inc. (ZVRA) reported discount and rebate liabilities, less current portion of $9.48M in Q1 2026.
How has Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion changed year-over-year?
Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion increased by 1.0% year-over-year, from $9.39M to $9.48M.
What is the long-term trend for Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion?
Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion has grown at a 30.8% compound annual growth rate (CAGR), from $4.33M to $9.69M.